Top news of the week from Pharmacy Times®.
Hepatitis/MASH
Latest News
Advertisement
CME Content
Advertisement
Regular testing for hepatitis C virus has proven more effective than targeted testing.
Which product caused hepatic failure?
Organ transplants from seropositive donors carry a high risk of infection from the transplanted organ.
Although lifesaving drugs became available around 1998 to treat hepatitis C, they were expensive, which limited access for some patients.
The 2 most common, recommended, and simplified treatments for HCV are glecaprevir/pibrentasvir (Mavyret) and sofosbuvir/velpatasvir (Epclusa).
The drug was previously approved to treat HCV in adults
http://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.pdf?la=en
The immunogenicity and safety of hepatitis B surface antigen (HBsAg)/CpG 1018 was assessed in patients with diabetes aged 60 to 70 years.
The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.
Chronic hepatitis B virus (HBV), which affects an estimated 862,000 individuals in the United States, is caused by long-term infection with the virus and can lead to serious liver damage.
Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.
Transplanting organ from patients infected with hepatitis C could greatly expand the number of kidneys available and reduce wait times.
Top news of the day from across the health care landscape.
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Top news of the day from across the health care landscape.
The hepatitis B virus (HBV) is spread through contact with infected blood or bodily fluids, usually passing into a host via damaged skin (eg, lesions, needlesticks) or mucous membranes, such as the eyes or genitalia.
Top news of the day from across the health care landscape.
Receptor-modified T cells successfully controlled chronic hepatitis B virus, showing promise as a potential cure for the disease.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
This drug was previously approved, in 2017, to treat HCV in adults.
Glecaprevir/pibrentasvir (G/P) plus sofosbuvir and ribavirin can potentially treat patients who experienced previous virologic failure following G/P therapy.
HIV infection is associated with higher rates of hepatitis C replication.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
2
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
3
FDA Approves Dolutegravirfor HIV Treatment in Newborns
4
FDA Clears First Continuous Glucose-Ketone Monitor
5